| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AMIXAutonomix Medical, Inc. Common Stock | 3.59M | 0.52 | -0.08 | -258.98% | ||||
| CBLLCeriBell, Inc. | 847.27M | 22.84 | -6.74 | 44.71% | -63.35% | -31.97% | 0.11 | |
| NMTCNeuroOne Medical Technologies Corporation | 45.32M | 0.90 | -9.99 | 250.35% | -39.63% | -50.98% | 0.04 | |
| CLPTClearPoint Neuro, Inc. | 435.81M | 14.65 | -20.93 | 31.04% | -67.4% | -145.77% | 0.14 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 25.92M | 45.23M | 65.44M |
| Revenue Growth % | - | 0.74% | 0.45% |
| Cost of Goods Sold | 4.43M | 7.06M | 8.69M |
| COGS % of Revenue | 0.17% | 0.16% | 0.13% |
| Gross Profit | 21.49M | 38.16M | 56.75M |
| Gross Margin % | 0.83% | 0.84% | 0.87% |
| Gross Profit Growth % | - | 0.78% | 0.49% |
| Operating Expenses | 57.51M | 68.2M | 96.46M |
| OpEx % of Revenue | 2.22% | 1.51% | 1.47% |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M |
| SG&A % of Revenue | 1.94% | 1.31% | 1.27% |
| Research & Development | 7.24M | 8.99M | 13.56M |
| R&D % of Revenue | 0.28% | 0.2% | 0.21% |
| Other Operating Expenses | 0 | 0 | 0 |
| Operating Income | -36.02M | -30.04M | -39.71M |
| Operating Margin % | -1.39% | -0.66% | -0.61% |
| Operating Income Growth % | - | 0.17% | -0.32% |
| EBITDA | -35.52M | -29.19M | -38.57M |
| EBITDA Margin % | -1.37% | -0.65% | -0.59% |
| EBITDA Growth % | - | 0.18% | -0.32% |
| D&A (Non-Cash Add-back) | 497K | 847K | 1.14M |
| EBIT | -35.56M | -27.36M | -38.46M |
| Net Interest Income | -1.6M | -2.1M | -1.99M |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M |
| Other Income/Expense | -1.14M | 588K | -746K |
| Pretax Income | -37.16M | -29.45M | -40.45M |
| Pretax Margin % | -1.43% | -0.65% | -0.62% |
| Income Tax | 2K | 11K | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -37.16M | -29.46M | -40.45M |
| Net Margin % | -1.43% | -0.65% | -0.62% |
| Net Income Growth % | - | 0.21% | -0.37% |
| Net Income (Continuing) | -37.16M | -29.46M | -40.45M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -1.59 | -1.26 | -3.39 |
| EPS Growth % | - | 0.21% | -1.69% |
| EPS (Basic) | -1.59 | -1.26 | -3.39 |
| Diluted Shares Outstanding | 23.32M | 23.32M | 11.95M |
| Basic Shares Outstanding | 23.32M | 23.32M | 11.95M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 79.8M | 51.96M | 217.27M |
| Cash & Short-Term Investments | 68.23M | 34.49M | 194.37M |
| Cash Only | 68.23M | 34.49M | 194.37M |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 5.29M | 7.96M | 10.88M |
| Days Sales Outstanding | 74.56 | 64.2 | 60.67 |
| Inventory | 4.08M | 5.87M | 6.94M |
| Days Inventory Outstanding | 335.75 | 303.29 | 291.24 |
| Other Current Assets | 2.19M | 3.65M | 5.09M |
| Total Non-Current Assets | 6.66M | 6.96M | 8.14M |
| Property, Plant & Equipment | 3.87M | 3.74M | 4.45M |
| Fixed Asset Turnover | 6.69x | 12.10x | 14.72x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 2.79M | 3.22M | 3.69M |
| Total Assets | 86.46M | 58.92M | 225.41M |
| Asset Turnover | 0.30x | 0.77x | 0.29x |
| Asset Growth % | - | -0.32% | 2.83% |
| Total Current Liabilities | 9.86M | 21.6M | 12.99M |
| Accounts Payable | 423K | 732K | 1.14M |
| Days Payables Outstanding | 34.85 | 37.83 | 47.99 |
| Short-Term Debt | 2.5M | 11.83M | 0 |
| Deferred Revenue (Current) | 343K | 206K | 97K |
| Other Current Liabilities | 2.51M | 3.73M | 5M |
| Current Ratio | 8.09x | 2.41x | 16.73x |
| Quick Ratio | 7.68x | 2.13x | 16.19x |
| Cash Conversion Cycle | 375.46 | 329.66 | 303.92 |
| Total Non-Current Liabilities | 162.99M | 149.57M | 21.26M |
| Long-Term Debt | 12.72M | 0 | 19.56M |
| Capital Lease Obligations | 2.37M | 1.68M | 1.31M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 147.9M | 147.85M | 356K |
| Total Liabilities | 172.86M | 171.17M | 34.25M |
| Total Debt | 18.22M | 14.2M | 21.96M |
| Net Debt | -50.02M | -20.29M | -172.41M |
| Debt / Equity | - | - | 0.11x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -22.47x | -14.32x | -19.93x |
| Total Equity | -86.4M | -112.25M | 191.16M |
| Equity Growth % | - | -0.3% | 2.7% |
| Book Value per Share | -3.70 | -4.81 | 16.00 |
| Total Shareholders' Equity | -86.4M | -112.25M | 191.16M |
| Common Stock | 5K | 5K | 36K |
| Retained Earnings | -97.03M | -126.49M | -166.94M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -32M | -29.16M | -35.04M |
| Operating CF Margin % | -1.23% | -0.64% | -0.54% |
| Operating CF Growth % | - | 0.09% | -0.2% |
| Net Income | -37.16M | -29.46M | -40.45M |
| Depreciation & Amortization | 497K | 847K | 1.14M |
| Stock-Based Compensation | 7.93M | 2.68M | 5.41M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 621K | 477K | 2.03M |
| Working Capital Changes | -3.88M | -3.7M | -3.17M |
| Change in Receivables | -3.96M | -3.43M | -3.51M |
| Change in Inventory | -1.9M | -1.79M | -1.07M |
| Change in Payables | 124K | 309K | 250K |
| Cash from Investing | -1.4M | -1.76M | -1.6M |
| Capital Expenditures | -516K | -983K | -1.34M |
| CapEx % of Revenue | 0.02% | 0.02% | 0.02% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | -883K | -780K | -258K |
| Cash from Financing | 49.8M | -2.82M | 196.52M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 154K | 932K | -304K |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -32.52M | -30.14M | -36.38M |
| FCF Margin % | -1.25% | -0.67% | -0.56% |
| FCF Growth % | - | 0.07% | -0.21% |
| FCF per Share | -1.39 | -1.29 | -3.04 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.99x | 0.87x |
| Interest Paid | 1.63M | 1.73M | 1.95M |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -102.53% |
| Gross Margin | 82.91% | 84.38% | 86.72% |
| Net Margin | -143.37% | -65.15% | -61.82% |
| Debt / Equity | - | - | 0.11x |
| Interest Coverage | -22.47x | -14.32x | -19.93x |
| FCF Conversion | 0.86x | 0.99x | 0.87x |
| Revenue Growth | - | 74.47% | 44.71% |
| 2024 | |
|---|---|
| Product | 50.08M |
| Product Growth | - |
| Subscription | 15.37M |
| Subscription Growth | - |
CeriBell, Inc. (CBLL) reported $82.8M in revenue for fiscal year 2024. This represents a 219% increase from $25.9M in 2022.
CeriBell, Inc. (CBLL) grew revenue by 44.7% over the past year. This is strong growth.
CeriBell, Inc. (CBLL) reported a net loss of $52.5M for fiscal year 2024.
CeriBell, Inc. (CBLL) has a return on equity (ROE) of -102.5%. Negative ROE indicates the company is unprofitable.
CeriBell, Inc. (CBLL) had negative free cash flow of $41.2M in fiscal year 2024, likely due to heavy capital investments.